title: [Monitoring options and reversal agents for oral anticoagulants].
abstract: The approval of the oral direct thrombin inhibitor dabigatranetexilat and the oral factor Xa inhibitors rivaroxaban and apixaban as thromboprophylaxis challenges the position of the vitamin K antagonists (VKA). Predictable pharmacodynamics gives the new oral anticoagulants an advantageous profile. Unlike VKAs there is no specific reversal agent available for the new oral anticoagulants. Experience with haemostatic products for the emergency management of critical bleeding caused by these agents is limited.
authors.affiliation: Skovbrynet 13, 9530 Støvring. sbthorup@dadlnet.dk.
authors.forename: Stine Borch
authors.initials: SB
authors.lastname: Thorup
authors.forename: Steen Elkjær
authors.initials: SE
authors.lastname: Husted
authors.forename: Marianne Lauridsen
authors.initials: ML
authors.lastname: Vang
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D000991:Antithrombins / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D001779:Blood Coagulation Factors / Q000627:therapeutic use; D001780:Blood Coagulation Tests; D000069604:Dabigatran / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D016903:Drug Monitoring / Q000379:methods*; D065427:Factor Xa Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D006470:Hemorrhage / Q000139:chemically induced / Q000188:drug therapy; D006801:Humans; D010949:Plasma; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D011728:Pyridones / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D000069552:Rivaroxaban / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D014812:Vitamin K / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000494:pharmacology
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D001779:Blood Coagulation Factors; D065427:Factor Xa Inhibitors; D011720:Pyrazoles; D011728:Pyridones; D014812:Vitamin K; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran